Oncternal Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating cancer treatments for diseases where current medical options are insufficient. Its clinical-stage portfolio features zilovertamab, a humanized monoclonal antibody designed to bind to ROR1 (Receptor-tyrosine kinase-like Orphan Receptor 1), and ONCT-216, a small molecule that works by inhibiting the biological activity of ETS-family transcription factor oncoproteins. Additionally, Oncternal is advancing ONCT-808, a chimeric antigen receptor T-cell (CAR-T) therapy candidate also targeting ROR1, as well as ONCT-534, a dual-action androgen receptor inhibitor aimed at treating castration-resistant prostate cancer and other cancers driven by androgen receptors.
| Date | Est. | Actual | |
|---|---|---|---|
| Nov 6, 2024 | -$3.22 | -$2.86 | Beat |
| Aug 8, 2024 | -$3.03 | -$2.89 | Beat |
| May 9, 2024 | -$2.88 | -$2.83 | Beat |
| Mar 7, 2024 | -$3.09 | -$3.11 | Miss |
| Nov 9, 2023 | -$3.00 | -$3.40 | Miss |
| Aug 10, 2023 | -$3.40 | -$3.00 | Beat |